Protalex, Inc.

Protalex, Inc.

  • 145 Union Square Drive
  • New Hope, Pennsylvania
  • 18938

Website Links

Press releases
Contact us

Description

The company’s lead compound, PRTX-100, is currently in development for idiopathic thrombocytopenic purpura, a rare blood clotting disorder, and rheumatoid arthritis. PRTX-100, a highly-purified form of Staphylococcal Protein A (SpA or Protein A) has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. Protalex believes that direct administration of PRTX-100 via I.V. bolus will prove a much more effective therapy for these and other indications.

Companies nearby